Ankylosing spondylitis
Conditions
Interventions
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Compliant with the revised AS New York standards of 1984; 2. Voluntarily sign the informed consent form; 3. Age >= 18 years old; 4. Experienced failure of adalimumab treatment (decided by the attending physician based on clinical judgment); 5. The clinical decision has been made to switch to an IL-17A inhibitor as the next-line treatment.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously used secukinumab; 2. Patients who have used other biological agents before using adalimumab; 3. Patients currently using immunosuppressive agents (such as tacrolimus, glucocorticoids, etc.); 4. Patients currently experiencing acute or chronic infections; 5. Pregnant women and lactating women; 6. Patients with malignant tumors; 7. Patients deemed unsuitable to participate in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug survival rate at 6 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease activity (ASDAS?CRP / BASDAI);Incidence of adverse events; | — |
Countries
China
Contacts
Public ContactLiqian Mo
Southern Medical University Southern Hospital
Outcome results
None listed